The twelve recommendations are intended to advise physicians on the use of imaging modalities when making a clinical diagnosis, and when to apply imaging for monitoring of disease activity and damage.
Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection.
For the treatment, including early rescue of Respiratory Distress Syndrome (RDS) or hyaline membrane disease in newborn babies. Prophylactic use in premature infants requiring intubation for stabilisation at risk from RDS or with evidence of surfactant deficiency.
Survanta is indicated for treatment of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in new born premature infants with a birth weight of 700g or greater. Survanta is also indicated for the prophylactic treatment of premature infants <32 weeks gestational age at risk of developing RDS who require intubation for stabilisation or with evidence of surfactant deficiency.